Clinical Trial

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Study acronym: ZYNERGY
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-11; most recent amendment 2026-07-06.
Trial Details
NCT Number NCT07589686
Lead Sponsor Hoffmann-La Roche
Collaborators: Zealand Pharma
Conditions Obesity or Overweight
Enrollment 486 participants
Start Date 2026-09-30
Primary Completion 2027-11-12 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-07